DDInter712 DDInter1940
Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</sub> receptor antagonists, famotidine displays high selectivity towards this receptor; in a study consisting of healthy volunteers and patients with acid hypersecretory disease, famotidine was about 20 to 50 times more potent at inhibiting gastric acid secretion than [cimetidine] and eight times more potent than [ranitidine] on a weight basis. Famotidine is used in various over-the-counter and off-label uses. While oral formulations of famotidine are more commonly used, the intravenous solution of the drug is available for use in hospital settings.
Vismodegib is an orally active small molecule that inhibits the hedgehog signaling pathway by binding to and inhibiting the transmembrane protein smoothened homologue (SMO).[A258613,A258618,L45803] It was discovered by high-throughput screening of a library of small-molecule compounds and subsequent optimization through medicinal chemistry. Since it targets the hedgehog signaling pathway, vismodegib has anti-tumor activity in basal-cell carcinoma. The Hedgehog signaling pathway plays an important role in the development of organs and tissues during embryogenesis. Afterwards, it is silenced in all cells and tissues, except for hair, skin and stem cells. However, dysregulated or aberrant Hedgehog signaling has been associated with basal cell carcinoma pathogenesis.[A258608,L45803] In January 2012, vismodegib was approved by the FDA for the treatment of adult basal cell carcinoma. In July 2013, it was approved by the EMA, and since then, it has been approved by several other countries.[A7370,A258618,L45803]
Famotidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Vismodegib
Famotidine {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Vismodegib
Famotidine {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Vismodegib
Famotidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sorafenib
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolvaptan
Tolvaptan {u} (Compound) resembles {v} (Compound) Vismodegib
Famotidine {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Vismodegib
Famotidine {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Vismodegib
Famotidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostemsavir
Fostemsavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sulfasalazine
Sulfasalazine {u} (Compound) resembles {v} (Compound) Vismodegib
Famotidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sorafenib
Sorafenib {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Vismodegib
Famotidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ketorolac
Ketorolac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sulfasalazine
Sulfasalazine {u} (Compound) resembles {v} (Compound) Vismodegib
Famotidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostemsavir
Fostemsavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Vismodegib
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib (Compound) resembles Vismodegib (Compound)
Famotidine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Vismodegib (Compound)
Famotidine (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Vismodegib (Compound)
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Tolvaptan and Tolvaptan (Compound) resembles Vismodegib (Compound)
Famotidine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Sorafenib (Compound) and Sorafenib (Compound) resembles Vismodegib (Compound)
Famotidine (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Sorafenib (Compound) and Sorafenib (Compound) resembles Vismodegib (Compound)
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine (Compound) resembles Vismodegib (Compound)
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Vismodegib (Compound)
Famotidine may cause a minor interaction that can limit clinical effects when taken with Ketorolac and Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine (Compound) resembles Vismodegib (Compound)
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib (Compound) resembles Vismodegib (Compound)